|
|
    |
|
  |
|
TAMAS BARTFAI, PH.D.
Director of the Harold L. Dorris Neurological Research Center and Professor of Neuropharmacology, The Scripps Research Institute. Tamas Bartfai is former head of central nervous system research at Hoffman-La Roche, in Basel, Switzerland. Formerly, he was Chairman of the Department of Neurochemistry and Neurotoxicology at Stockholm University in Sweden. He received his undergraduate education at Eotvos University and a Ph.D. in biochemistry at Stockholm University. He served as visiting scientist at Hadassah-Hebrew University Medical School, Jerusalem; Yale University Medical School; and the Neuropsychiatric Institute at University of California, Los Angeles. He holds Adjunct Professor appointments at Rockefeller University and Stanford University.
PAUL GREENGARD, PH.D.
Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at The Rockefeller University, Director of the Zachary and Elizabeth M. Fisher Center for Research on Alzheimer's Disease at Rockefeller, Professor Greengard is a graduate of The Johns Hopkins University. After postdoctoral studies in England and working as a researcher at the National Institutes of Health, he became director of biochemical research at the Geigy Research Laboratories in 1959. In 1968, he moved to Yale University to become professor and chair of neuropharmacology. In 1983, he joined The Rockefeller University. Dr. Greengard is an elected member of the National Academy of Sciences and its Institute of Medicine and of the American Academy of Arts and Sciences. He is the recipient of numerous awards and prizes including the 2000 Nobel Laureate in Physiology or Medicine.
HANNS MÖHLER, PH.D.
Professor of Pharmacology and Director of the Institute of Pharmacology and Toxicology at the Swiss Federal Institute of Technology, Zurich and the University of Zurich; Advisor, HBM Partners. Dr. Hanns Möhler joined the Board of Directors, as well as our Scientific Advisory Board in 2003. Dr. Möhler is currently a professor of pharmacology and the director of the Institute of Pharmacology and Toxicology at the Swiss Federal Institute of Technology and the University of Zurich. Dr. Möhler studied chemistry and biochemistry at the Universities of Bonn, Tubingen and Freiburg, Germany. He is Director of the Swiss National Research Center in Neuroscience and is a member of the Swiss Academy of Medical Sciences.
DONALD L. PRICE, M.D.
Professor of Pathology, Neurology and Neuroscience at The Johns Hopkins University School of Medicine, and currently Director of the Division of Neuropathology and Director of Alzheimer's Disease Research Center at Johns Hopkins. He also serves as the current President of the Society of Neuroscience, and is a recipient of numerous awards for his pioneering work in the use of gene targeting and molecular approaches to the study of neurodegenerative diseases.
PETER SEEBURG, PH.D.
Professor of Molecular Biology at the University of Heidelberg in Germany, and currently Director of the Department for Molecular Neurobiology at the Max Planck Institute for Medical Research. Dr. Seeburg was an early pioneer in biotechnology at Genentech, and is one of the most cited authors in neurosciences and recipient of numerous awards for his work in molecular properties of neurotransmitter receptors.
TADEUSZ WIELOCH, PH.D.
Professor of Neurobiology at the University of Lund the Wallenberg Neuroscience Center in Sweden. Dr. Wieloch has been a pioneer investigating the mechanisms of brain damage following cerebral ischemia and hypoglycemia, and mechanisms of brain protection by hypothermic and ischemic preconditioning, and more recently mechanisms of functional recovery of the brain after stroke. He has made fundamental discoveries on the involvement of glutamate, as well as aberrant cell signaling and mitochondria in cell death after ischemia. |
|
